Since 2014, use of oral direct-acting antivirals (DAAs) has been the standard of care for hepatitis C and results in cure rates of greater than 95% with 8 to 12 weeks of treatment.
1 Although the US has a goal of eliminating hepatitis C as a public health threat by 2030, the number of estimated new hepatitis C virus (HCV) infections has more than doubled from 24 700 in 2012 to 69 800 in 2021.
2,3 After an initial surge of people being treated after the release of DAAs, the number of people treated for hepatitis C has steadily declined from a peak of 164 247 people in 2015 to 83 740 people in 2020.
4 Previous modeling has suggested that a mean of 260 000 people must be treated each year to reach hepatitis C elimination targets.
5 Despite an estimate of more than 1 million people treated with DAAs in the US since 2014, only 34% of people with diagnosed infection had evidence of viral clearance, and the number of people with hepatitis C nationally remained stable from 2.1 million in 2013 to 2016 to 2.2 million in 2017 to 2020.
6,7 Many more people with hepatitis C need to be treated to reach national hepatitis C elimination targets.